[EN] CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] CARBOXAMIDES UTILISÉES EN TANT QU'INHIBITEURS DE PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE
申请人:FORMA THERAPEUTICS INC
公开号:WO2019032863A1
公开(公告)日:2019-02-14
The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
Pyrido[3',2':4,5]thieno[3,2-d]-N-triazines: a new series of orally active antiallergic agents
作者:Raymond D. Youssefyeh、Richard E. Brown、Jeffrey Wilson、Uresh Shah、Howard Jones、Bernard Loev、Atul Khandwala、Mitchell J. Leibowitz、Paula Sonnino-Goldman
DOI:10.1021/jm00378a019
日期:1984.12
A newseries of orallyactive mediator release inhibitors, pyrido[3',2':4,5]thieno[3,2-d]-N-triazines, was synthesized and evaluated for antiallergic activity. Several products showed high activity as inhibitors or wheal information in the rat passive cutaneous anaphylaxis screen and as inhibitors of histamine release from passively sensitized rat mast cells. Many compounds were orallyactive in the
Ho, Yuh Wen; Wang, Ing Jing, Journal of Heterocyclic Chemistry, 1995, vol. 32, # 3, p. 819 - 826
作者:Ho, Yuh Wen、Wang, Ing Jing
DOI:——
日期:——
Compounds that Inhibit HIV Particle Formation
申请人:Rekosh David
公开号:US20110152301A1
公开(公告)日:2011-06-23
The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV.
[EN] CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] CARBOXAMIDES EN TANT QU'INHIBITEURS DE PROTÉASE SPÉCIFIQUES DE L'UBIQUITINE
申请人:FORMA THERAPEUTICS INC
公开号:WO2020033707A1
公开(公告)日:2020-02-13
The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.